THE ROLE OF TISSUE KALLIKREIN IN THE BLOOD COAGULATION SYSTEM IN VICTIMS WITH CLOSED CRANIOCEREBRAL INJURY

Article Sidebar

PDF (Russian)
Published: 2022-10-05
DOI: https://doi.org/10.66073/researchfocus.v1i1.1058
Keywords:
CCCI (closed craniocerebral injury), tissue kallikrein (kallidinogenase), coagulogram

Main Article Content

Avakov V.Ye.
Tashkent Medical Academy, Department of Anesthesiology and Intensive Care
Ibragimov N. K.
Kenjayev L.T.
Jurakulov A.K.
Naubetova S. D.
Sharapav M.M.
Durdiyev X.U.

Abstract

The treatment of victims with closed craniocerebral injury (CCCI) is a pressing task of modern medicine and has great socio-economic significance. Closed craniocerebral injury is a traumatic damage of the brain, representing primary and secondary damage of brain tissue and an increase in intracranial pressure, which leads to a temporary or permanent disturbance of brain function. Kallidinogenase - tissue kallikrein, a component of the kallikrein-kinin system (KKS), has a protective action against cerebral ischemia.

Article Details

Issue

Vol. 1 No. 1 (2022): Research Focus International Scientific Journal. Volume 1, Issue 1 (2022)

Section

Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

THE ROLE OF TISSUE KALLIKREIN IN THE BLOOD COAGULATION SYSTEM IN VICTIMS WITH CLOSED CRANIOCEREBRAL INJURY. (2022). Research Focus International Scientific Journal, 1(1), 201-207. https://doi.org/10.66073/researchfocus.v1i1.1058

References

Аваков В.Е., Шахова И.А. Терапевтическая гипотермия и контролируемая нормотермия в практике интенсивной терапии острой ишемии головного мозга: состояние кардиоваскулярной системы. Вестник экстренной медицины. 2015 – №2. – С.24-29.

Акмалов А.С. Оптимизация защиты мозга у больных тяжелой черепно-мозговой травмой. Диссертационная работа. 2006.

Сабиров Д.М., Росстальная А.Л., Махмудов М.А. Эпидемиологические аспекты черепно-мозгового травматизма. Вестник экстренной медицины.2019 том 12 №2 С.61- 66.

Chauhan N.B. Chronic neurodegenerative consequences of traumatic brain injury. Restor. Neurol. Neurosci. 2014, 32, 337–365.

De Bellis, A., Bellastella, G. et all. The role of autoimmunity in pituitary dysfunction due to traumatic brain injury. Pituitary 2019, 22, 236–248.

Dewan M.C., Rattani, A., et all. Estimating the global incidence of traumatic brain injury. J. Neurosurg. 2018, 27, 1–18.

Feigin VL.V., Theadom A., et al, and the BIONIC Study Group. Incidence of traumatic brain injury in New Zealand-a population-based study. Lancet Neurol 2013. 12: 53-64.

Johnson V.E. Stewart W. all. Axonal pathology in traumatic brain injury. Exp. Neurol. 2013, 246, 35–43.

Joseph B., Haider A., et. all. Traumatic brain injury advancements. Curr Opin Crit Care – 2015. – №21. – P.506-511.

Olesen J., Gustavsson A., et. all. The economic cost of brain disorders in Europe. Eur J.Neurol – 2012. – №19. – P. 155-162.

Oratile K., Osamah H., et. all. Growth Hormone Deficiency Following Traumatic Brain Injury. Int. J. Mol. Sci. 2019, 20, 3323

Maas A.I.R., Menon D.K. et al. Traumatic brain injury- integrated approaches to improve prevention, clinical care, and research. Lancet Neurology. 2017. 16 (12). pp. 987-1048. ISSN 1474-4422.

Sayed I.A., Shafiq U.R. et all. Nicotinamide Improves Functional Recovery via Regulation of the RAGE/JNK/NF-κB Signaling Pathway after Brain Injury. J. Clin. Med. 2019, 8, 271.

Stein S.C., Georgoff P., et. all. 150 years of treating severe traumatic brain injury: A systematic review of progress in mortality. J Neurotrauma. – 2010. – №27. – P.1343-1353.

Teasdale G., Jennett, B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974, 2, 81–84.

Veenith, T., Goon S.S.H., et all. Molecular mechanisms of traumatic brain injury: The missing link in management. World J. Emerg. Surg. 2009, 4, 7.

Xiping Yang, Yisheng Chen, et. all. Hypertonic saline maintains coagulofibrinolytic homeostasis following moderate to severe traumatic brain injury by regulating monocyte phenotype via expression of lncRNAs. Molecular medicine reports. 2019. –№19. – P.1083-1091.

В. А. Бывальцев, А. А. Калинин, Е. Г. Белых. Черепно-мозговая травма. ФГБОУ ВО ИГМУ Минздрава России, 2018. 616.833.1-001-089(0758).

Царенко C.B. Современные подходы к интенсивной терапии тяжёлой черепно-мозговой травмы / C.B. Царенко //Анестезиология и реаниматология 2003. - №2.- С. 45-49.

Cuny E. Physiopathology of chronic subdural hematoma. / E. Cuny // Neurochirurgie. 2001. - Vol. 47, № 5. 464-468.

Гемостаз и сосудистый эндотелий при черепно-мозговой травме. В.В. Семченко, А.Ю. Войнов, З.Ш. Голевцова и др. Омск-Надым: Омская областная типография,2003.168 с.

Епифанцева H.H. Механизмы нарушений гемостаза при черепно-мозговой травме и способы их коррекции: дис. . канд. мед. наук./H.H. Епифанцева.Томск, 2001.150с.

Исследование реологических свойств крови и их связь с лёгочной гипертензией у больных с ХОБЛ / O.JI. Осипова, В.Е. Перлей, Г.П. Орлова и др. // Клиническая лабораторная диагностика -2004.-№8.-С. 30-31.

Воинов А.Ю. Антитромбогенный потенциал сосудистой стенки и процессы гемостаза при ЧМТ: автореф. дис. К.м.н /А.Ю. Воинов. Омск, 2002.18 с.

Traumatic brain injury.Gordon Mao MD, Johns Hopkins School of Medicine 202.

Беленичев И.Ф. и др. Нейропротекция и нейропластичность. К.Логос,2015.512с.

Regoli D and Gobeil F. Critical insights into the beneficial and protective actions of the kallikrein-kinin system/ Vascul Pharmacol 2015; 64: 1-10.

Whalley ET, Figueroa CD, Gera L, Bhoola, KD. Discovery and therapeutic potential of kinin receptor antagonists.Expert Opin Drug Discov.(2012) 7:1129–48.doi: 10.1517/17460441.2012.729038 .

Chao J, Chao L. Experimental Therapy with Tissue Kallikrein against Cerebral Ischemia. Front Biosci. 2006; 11:1323-7.

Zhang C, Tao W, Liu M, Wang D. Efficacy and Safety of Human Urinary Kallidinogenase Injection for Acute Ischemic Stroke: A Systematic Review. J Evid Based Med.2012; 5:31-9.

Michel A.K Rick Pols John. John J.W. Filip M. Batt and Todd A. Tkanevoy kalliykrien cheloveka pri lesheniy ostrovo ishiymisheskovo insulta.her Adv Neural Disord 2019. Vol 12: 1-15 DOI:10.1177/1756286418821918.